Life sciences & pharmaceuticals

A fast-changing sector

In today’s climate of change (tougher regulatory constraints, loss of patents, intensified competition and the emergence of new markets), the pharmaceutical industry has undertaken to dynamically change its business model, conduct organizational transformations and improve its performance. Oresys assists many laboratories with this challenge and helps them take advantage of today’s new opportunities. Our teams have in-depth knowledge of this sector, coupled with expertise in major business transformation programs and experience in pressing contexts

Our experience

Last year, nearly 50 consultants took part in over 30 assignments in this sector. We have been supporting numerous actors of the pharmaceutical industry for over 15 years and providing innovative and adapted solutions to their needs.

A founding member of Cordence Worldwide, Oresys offers its clients an international dimension, together with a worldwide network of experts, to shoulder their international projects.

Oresys has provided major transformation project support to a variety of departments: Top Management, R&D, Industry, Marketing & Operations Commercial, Finance and IT.

Our offer

Oresys provides high-level consultancy services for transformation project scoping, definition and implementation, together with wide-reaching know-how and services:

  • Implementation of new Business Models (creation of an intrapreneurial entity within a laboratory, international steering of partnership projects, etc.)
  • Transformation project steering (reorganization of R&D, international redeployment and improvement of functioning with local subsidiaries, etc.)
  • Optimization of the product & project portfolio
  • Improved awareness of the project culture and rollout of R&D steering methods
  • Operational Excellence
  • IS optimization (repositories, planning, etc.)
  • Professionalization of IT Depts.

They trust us

Servier, Novartis, Johnson&Johnson, Sanofi, Mérial, Ferring, BioMérieux, Galderma, Ipsen, UCB Pharma…

Your correspondent Your correspondent